Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Riliprubart · SAR-445088, BIVV-020

Other · developed by Sanofi

Phase 3 Most advanced trial
SNY Developer
2 Registered trials

What is Riliprubart?

Riliprubart (SAR445088, BIVV-020) is a drug given as an intravenous or subcutaneous solution.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
SAR-445088, BIVV-020
Drug type
Other
Therapy area
Neurology
Developer
Sanofi (SNY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
I31869XDP8

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06290141 Phase 3 Chronic Inflammatory Demyelinating Polyneuropathy Recruiting SNY
NCT04658472 Phase 2 Chronic Inflammatory Demyelinating Polyradiculoneuropathy Completed SNY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Inflammatory Demyelinating PolyneuropathyChronic Inflammatory Demyelinating Polyradiculoneuropathy

More from Sanofi

Sources

Updated Nov 22, 2026. Something wrong or missing? Report it on the SNY page.

Follow SNY, the company behind Riliprubart

See SNY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SNY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.